VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
VolitionRx Limited reports significant clinical and commercial progress in the first half of 2026, including validation of its Nu.Q® NETs assay for severe sepsis detection, new use cases for trauma care and chronic diseases, and advancements in a finger-prick lateral flow assay for nucleosome detection. The company aims to penetrate large global markets and enhance its product offerings in cancer management, particularly lung cancer.
112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON, Nev., Aug. 26, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a…